Phenotypic Age AccelerationNCT07595094
Phenotypic Age Acceleration (PhenoAgeAccel) for Joint Prediction of Disease Risk, Mortality Risk, Life Expectancy, and Disease-Free Healthspan in Major Chronic Diseases
An observational study of Phenotypic Age Acceleration and Biological Aging Marker, run by Second Affiliated Hospital of Nanchang University at 1 site in China.
Trial summary
The goal of this observational study is to learn about the ability of Phenotypic Age Acceleration (PhenoAgeAccel) to predict four key health outcomes in Chinese people with or at risk of major chronic diseases: the risk of developing new chronic diseases, the risk of dying, life expectancy, and disease-free… Read more about this study
- Who is it for?
- Ages 35 years and olderHealthy volunteers can take part
- Conditions the study is for
- Phenotypic Age Acceleration, Biological Aging Marker, Mortality Risk Prediction
- How many people
- 2,000,000 participants
- Where
- 1 siteChina
- Study dates
- 1 Jun 2006to 30 Jun 2030
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study population consists of Chinese adults aged 35-73 years from multicenter clinical cohorts in northern and southern China, with complete routine blood test data available at baseline. All participants are patients receiving routine care at collaborating hospitals. Data are prospectively collected via electronic medical records to analyze the association between Phenotypic Age Acceleration and major chronic disease and mortality outcomes.
Who may be able to join
- Adults aged 35-73 years old. Complete routine blood test data available at baseline to calculate Phenotypic -Age (including albumin, alkaline phosphatase, creatinine, glucose, C-reactive protein, lymphocyte percentage, mean corpuscular volume, red cell distribution width, and white blood cell count).
- Complete demographic and clinical data (e.g., sex, BMI, comorbidities) available at baseline.
- Consent to use routine medical data for research follow-up analysis.
Who cannot join
- Presence of end-stage diseases (e.g., end-stage liver/renal failure) other than the major chronic diseases of interest at baseline.
- Key baseline data missing, making Phenotypic Age calculation impossible. Incomplete follow-up information or inability to confirm outcomes (e.g., death, disease onset) via database linkage.
- Refusal to participate in the study or withdrawal of informed consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006
Xi-Jian Dai Xi-Jian Dai, MD, +86-137-5575-6959, daixjdoctor@126.com
daixjdoctor@126.com
About this study
The goal of this observational study is to learn about the ability of Phenotypic Age Acceleration (PhenoAgeAccel) to predict four key health outcomes in Chinese people with or at risk of major chronic diseases: the risk of developing new chronic diseases, the risk of dying, life expectancy, and disease-free healthspan.
The main questions this study aims to answer are:
Read more
- Does higher PhenoAgeAccel increase the risk of developing major chronic diseases (including diabetes, dementia, cancer, and chronic respiratory diseases) in Chinese adults?
- Does higher PhenoAgeAccel increase the risk of death from all causes in Chinese adults?
- How do life expectancy and disease-free healthspan differ between people with high versus low PhenoAgeAccel?
Who can take part in this study? Adults aged 35 or above years old who receive routine care at participating hospitals in China, have complete routine blood test data available, and have provided consent to use their health information for research purposes.
What will participants go through? Participants will receive their usual medical care as they normally would. No new treatments, tests, or procedures will be performed specifically for this study. We will collect data from their medical records, including blood test results used to calculate PhenoAgeAccel, diagnoses of new diseases, and dates of death.
What are the potential benefits? Participants will not receive direct personal benefits from taking part in this study. However, the information learned may help us better understand biological aging and improve future risk assessment and health management for people with chronic diseases.
Is this study safe? Yes. This is an observational study that does not involve any new drugs, devices, or invasive procedures. All data used in the study will be de-identified and kept strictly confidential to protect participants' privacy.
- Conditions
- Phenotypic Age Acceleration, Biological Aging Marker, Mortality Risk Prediction, Disease Risk Prediction, Life Expectancy, Disease-Free Healthspan
- Being tested
- No Intervention (Observational Study)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No Intervention (Observational Study)Other
This is an observational study with no study-specific intervention. All participants receive their routine standard medical care as usual. No new drugs, devices, procedures, or behavioral modifications are assigned as part of this research.
| Study group | Role | What they receive |
|---|---|---|
| Non-accelerated PhenoAge Group | Participants with normal biological aging, defined as Phenotypic Age Acceleration ≤ 0. No study-specific intervention is administered; all participants receive routine clinical care as usual. Receives: Other: No Intervention (Observational Study) | |
| Mildly Accelerated PhenoAge Group | Participants with mild biological aging acceleration, defined as 0 < Phenotypic Age Acceleration < median. No study-specific intervention is administered; all participants receive routine clinical care as usual. Receives: Other: No Intervention (Observational Study) | |
| Severely Accelerated PhenoAge Group | Participants with severe biological aging acceleration, defined as Phenotypic Age Acceleration ≥ median. No study-specific intervention is administered; all participants receive routine clinical care as usual. Receives: Other: No Intervention (Observational Study) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Major Chronic Diseases
Composite incidence of new-onset major chronic diseases, including type 2 diabetes, dementia, cancer, and chronic respiratory diseases, defined by ICD-10 codes from electronic medical records.
Measured: Baseline through study completion, average 10 years
All-Cause Mortality
All-cause mortality, defined as death from any cause, identified through linkage with death registration databases.
Measured: Baseline through study completion, average 10 years
Secondary outcomes (2)
Life Expectancy
Estimated remaining life expectancy stratified by biological aging status (PhenoAgeAccel) using parametric survival models.
Measured: Baseline through study completion, average 10 years
Disease-Free Healthspan
Estimated years of life free from major chronic diseases, calculated as the difference between life expectancy and time spent with chronic diseases
Measured: Baseline through study completion, average 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 May 2026
- Study start1 Jun 2006
- Primary completion1 Jun 2030 (estimated)
- Study completion30 Jun 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Phenotypic Age AccelerationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,000,000 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Second Affiliated Hospital of Nanchang University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07595094
- Sponsor's protocol ID
- IIT-O-2024-136
- Status last verified
- May 2026
- First submitted
- 8 May 2026
- Last updated
- 19 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phenotypic Age Acceleration (PhenoAgeAccel) for Joint Prediction of Disease Risk, Mortality Risk, Life Expectancy, and Disease-Free Healthspan in Major Chronic Diseases
- ClinicalTrials.gov ID
- NCT07595094
- Acronym / sponsor ID
- IIT-O-2024-136
- Conditions
- Phenotypic Age Acceleration, Biological Aging Marker, Mortality Risk Prediction, Disease Risk Prediction, Life Expectancy, Disease-Free Healthspan
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 2,000,000 participants (estimated)
- Lead sponsor
- Second Affiliated Hospital of Nanchang UniversityUniversity, hospital or other
- Study start
- 1 Jun 2006 (actual)
- Primary completion
- 1 Jun 2030 (estimated)
- Study completion
- 30 Jun 2030 (estimated)
- First posted
- 19 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn about the ability of Phenotypic Age Acceleration (PhenoAgeAccel) to predict four key health outcomes in Chinese people with or at risk of major chronic diseases: the risk of developing new chronic diseases, the risk of dying, life expectancy, and disease-free healthspan.
The main questions this study aims to answer are:
- Does higher PhenoAgeAccel increase the risk of developing major chronic diseases (including diabetes, dementia, cancer, and chronic respiratory diseases) in Chinese adults?
- Does higher PhenoAgeAccel increase the risk of death from all causes in Chinese adults?
- How do life expectancy and disease-free healthspan differ between people with high versus low PhenoAgeAccel?
Who can take part in this study? Adults aged 35 or above years old who receive routine care at participating hospitals in China, have complete routine blood test data available, and have provided consent to use their health information for research purposes.
What will participants go through? Participants will receive their usual medical care as they normally would. No new treatments, tests, or procedures will be performed specifically for this study. We will collect data from their medical records, including blood test results used to calculate PhenoAgeAccel, diagnoses of new diseases, and dates of death.
What are the potential benefits? Participants will not receive direct personal benefits from taking part in this study. However, the information learned may help us better understand biological aging and improve future risk assessment and health management for people with chronic diseases.
Is this study safe? Yes. This is an observational study that does not involve any new drugs, devices, or invasive procedures. All data used in the study will be de-identified and kept strictly confidential to protect participants' privacy.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 10 Years
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Non-accelerated PhenoAge Group | – | Other: No Intervention (Observational Study)Participants with normal biological aging, defined as Phenotypic Age Acceleration ≤ 0. No study-specific intervention is administered; all participants receive routine clinical care as usual. |
| Mildly Accelerated PhenoAge Group | – | Other: No Intervention (Observational Study)Participants with mild biological aging acceleration, defined as 0 < Phenotypic Age Acceleration < median. No study-specific intervention is administered; all participants receive routine clinical care as usual. |
| Severely Accelerated PhenoAge Group | – | Other: No Intervention (Observational Study)Participants with severe biological aging acceleration, defined as Phenotypic Age Acceleration ≥ median. No study-specific intervention is administered; all participants receive routine clinical care as usual. |
Who may qualify
- Ages
- 35 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study population consists of Chinese adults aged 35-73 years from multicenter clinical cohorts in northern and southern China, with complete routine blood test data available at baseline. All participants are patients receiving routine care at collaborating hospitals. Data are prospectively collected via electronic medical records to analyze the association between Phenotypic Age Acceleration and major chronic disease and mortality outcomes.
Key inclusion criteria (3 listed)
- Adults aged 35-73 years old. Complete routine blood test data available at baseline to calculate Phenotypic -Age (including albumin, alkaline phosphatase, creatinine, glucose, C-reactive protein, lymphocyte percentage, mean corpuscular volume, red cell distribution width, and white blood cell count).
- Complete demographic and clinical data (e.g., sex, BMI, comorbidities) available at baseline.
- Consent to use routine medical data for research follow-up analysis.
Key exclusion criteria (3 listed)
- Presence of end-stage diseases (e.g., end-stage liver/renal failure) other than the major chronic diseases of interest at baseline.
- Key baseline data missing, making Phenotypic Age calculation impossible. Incomplete follow-up information or inability to confirm outcomes (e.g., death, disease onset) via database linkage.
- Refusal to participate in the study or withdrawal of informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No Intervention (Observational Study)This is an observational study with no study-specific intervention. All participants receive their routine standard medical care as usual. No new drugs, devices, procedures, or behavioral modifications are assigned as part of this research. | Other | Mildly Accelerated PhenoAge Group, Non-accelerated PhenoAge Group, Severely Accelerated PhenoAge Group |
Primary outcome
Incidence of Major Chronic Diseases
Time frame: Baseline through study completion, average 10 years
Composite incidence of new-onset major chronic diseases, including type 2 diabetes, dementia, cancer, and chronic respiratory diseases, defined by ICD-10 codes from electronic medical records.
All-Cause Mortality
Time frame: Baseline through study completion, average 10 years
All-cause mortality, defined as death from any cause, identified through linkage with death registration databases.
2 secondary outcomes
Life Expectancy
Time frame: Baseline through study completion, average 10 years
Disease-Free Healthspan
Time frame: Baseline through study completion, average 10 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 May 2026.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Phenotypic Age Acceleration and Biological Aging Marker, run by Second Affiliated Hospital of Nanchang University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xi-jian Dai, Doctor (13755756959, daixjdoctor@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Major Chronic Diseases (time frame: Baseline through study completion, average 10 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2026.